

- 1 The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-
- 2 dependent: a prospective observational study
- 3 Running title: Time-dependent agreement of antibody assays
- 4 Thomas Perkmann MD^{a*}, Patrick Mucher MSc^{a*}, Nicole Perkmann-Nagele MD^a, Astrid Radakovics MSc^a,
- 5 Manuela Repl^a, Thomas Koller MD^a, Klaus G Schmetterer MD PhD^a, Johannes W Bigenzahn MD PhD^a,
- 6 Florentina Leitner^a, Galateja Jordakieva MD PhD^b, Oswald F Wagner MD^a, Christoph J Binder MD PhD^a
- 7 and Helmuth Haslacher MD PhDa
- 8 *both authors contributed equally to the present manuscript
- 9 a Department of Laboratory Medicine, Medical University of Vienna, Austria
- 10 b Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of
- 11 Vienna, Austria
- 12 <u>Correspondence to:</u>
- 13 Helmuth Haslacher MD PhD MSc BSc BA, Medical University of Vienna, Department of Laboratory
- 14 Medicine, Waehringer Guertel 18-20, A-1090 Vienna, Austria, +43 1 40400 53190,
- 15 helmuth.haslacher@meduniwien.ac.at

16 Abstract

17 Objectives

19

20

21

22

24

25

27

29

30

32

34

35

36

37

18 Various commercial anti-Spike SARS-CoV-2 antibody tests are used for studies and in clinical settings

after vaccination. An international standard for SARS-CoV-2 antibodies has been established to achieve

comparability of such tests, allowing conversions to BAU/ml. This study aimed to investigate the

comparability of antibody tests regarding the timing of blood collection after vaccination.

Methods

23 For this prospective observational study, antibody levels of 50 participants with homologous AZD1222

vaccination were evaluated at 3 and 11 weeks after the first dose and 3 weeks after the second dose

using two commercial anti-Spike binding antibody assays (Roche and Abbott) and a surrogate

26 neutralization assay.

Results

28 The correlation between Roche and Abbott changed significantly depending on the time point studied.

Although 3 weeks after the first dose, Abbott provided values three times higher than Roche, 11 weeks

after the first dose, the values for Roche were twice as high as for Abbott, and 3 weeks after the second

31 dose even 5-6 times higher.

Conclusions

33 The comparability of quantitative anti-Spike SARS-CoV-2 antibody tests is highly dependent on the timing

of blood collection after vaccination. Therefore, standardization of the timing of blood collection might

be necessary for the comparability of different quantitative SARS-COV-2 antibody assays.

Keywords

SARS-CoV-2; serology; vaccination; agreement; time-dependency

Introduction

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Infectious diseases continue to pose a significant challenge for humanity, as the SARS-CoV-2 pandemic has again demonstrated¹. Nevertheless, in contrast to the past, diagnostic, therapeutic, and preventive strategies are now being developed at an unprecedented rate to address these pandemic challenges. Among all these strategies, however, one stands out: vaccination against SARS-CoV-2. Using new technologies and extensive knowledge on active immunization against numerous pathogens, highly efficient vaccines have been developed and applied within a few months². The vaccination aims to induce a SARS-CoV-2 specific immune response in analogy to a passed infection, which should protect against disease or even better against infection. The methodically simplest way to objectify a particular immune reaction is to measure infection- or vaccine-induced specific antibodies^{3,4}. Thus, antibody tests have been used for SARS-CoV-2 to confirm prior infection or detect unreported infections as part of seroprevalence surveys^{5–7}. Various antigens have been applied in this regard, which fall into two classes: SARS-CoV-2 nucleocapsid-specific antibodies and antibodies directed against the spike protein⁸. The latter antibodies, which are formed against components of the virus surface spike protein, are induced by all COVID vaccines currently in use, making them an ideal surrogate for the immune response after vaccination⁹. The need to establish quantitative assays to detect vaccine-induced antibodies was pointed out early on¹⁰. Furthermore, an international standard for SARS-CoV-2 antibodies (NIBSC 20/136) was issued by the WHO to improve the comparability of such assays¹¹. Although there is currently no general recommendation to determine antibody levels in all individuals after SARS-CoV-2 vaccination, this is reasonable from a scientific perspective in the search for a correlate of protection and has been done in numerous studies^{12–19}. Moreover, it is now known that suboptimal or even lack of response to vaccination can occur in specific groups like immunocompromised patients^{20–26}. These potential non-

responders might be identified in a first step by determining the antibody levels after vaccination.

Unfortunately, there is little scientific evidence on the real-life comparability of different commercially available quantitative test systems^{27–29}. We could previously show that referencing the WHO SARS-CoV-2 antibody standard by reporting standardized binding antibody units (BAU/mL) is insufficient for different test systems to provide numerically comparable results²⁷. We demonstrated this in a strictly standardized study setting concerning the time of blood collection and the vaccine used: three weeks after the first dose of BNT162b2. It was expected and has already been shown that antibody responses are dependent on the type of vaccine used^{30,31}. Moreover, time kinetics of post-vaccination antibody levels have been described for different vaccines and various antibody assays 17,32-37. However, whether and how these influencing factors affect the comparability of different quantitative SARS-CoV-2 antibody tests has not been systematically investigated. But answering these questions is fundamental to finding pragmatic ways to compare results from various SARS-CoV-2 antibody tests. In the present work, we aimed to expand knowledge on the comparability of quantitative anti-spike SARS-CoV-2 assays using another commonly administered vaccine, AZD1222, combined with antibody measurements at multiple time points: three weeks after the first vaccine dose, 11 weeks after the first dose (immediately before the second dose), and finally three weeks after the second dose. Moreover, pre- and post-booster levels were compared to SARS-CoV-2 specific T-cellular interferon γ responses. This design allowed us, utilizing two of the most commonly used commercially available assays applied in post-COVID vaccination antibody studies, the Roche Elecsys SARS-CoV-2 S-ECLIA³⁸⁻⁴¹ and the Abbott Anti-SARS-CoV-2 IgG II^{22,42,43}, to examine in detail the comparability of the assays concerning the timing of

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

blood collection after vaccination.

Methods

83

Study design and participants 84 85 We included sera of 50 participants in this prospective observational performance evaluation study. 86 Inclusion criteria were an age ≥18 years and willingness to donate blood in the course of the MedUni 87 Wien Biobank's healthy blood donor collection (Medical University of Vienna ethics committee vote No. 88 404/2012). Incomplete follow-up samples and seropositivity for anti-nucleocapsid antibodies due to 89 infection with SARS-CoV-2 lead to exclusion. The study protocol was reviewed and approved by the Medical University of Vienna ethics committee (1066/2021) and conforms with the Declaration of 90 Helsinki. 91 92 Laboratory methods Blood samples were taken 3 weeks and 11 weeks ("pre-booster") after the first dose of AZD1222, as well 93 94 as 3 weeks after dose 2. At pre- and post-booster time points, an additional amount of 4mL blood was 95 drawn to estimate T-cellular immunity (see Fig. 1). Blood samples were processed and stored according 96 to standard operating procedures by the MedUni Wien Biobank in an ISO 9001:2015 certified 97 environment 44. Previous SARS-CoV-2 infection was assessed by the Roche Elecsys SARS-CoV-2 nucleocapsid ECLIA 98 (Roche, Rotkreuz, Switzerland) on cobas e801 modular analyzers (Roche)⁴⁵. This assay detects total 99 100 antibodies against the viral nucleocapsid, which are induced after infection, but not after vaccination 101 with AZD1222. 102 Vaccine-induced antibodies against the viral spike protein were quantified using the Roche Elecsys SARS-CoV-2 S-ECLIA⁴⁶ and the Abbott Anti-SARS-CoV-2 IgG II^{47,48}. This Roche test is a quantitative (range: 0.4 – 103 104 2,500 BAU/mL) total antibody sandwich assay recognizing antibodies directed against the receptor-105 binding domain (RBD) of the SARS-CoV-2 spike (S) protein and was performed on cobas e801 modular

analyzers (Roche), samples >0.8 BAU/mL are considered diagnostically positive. As a deviation from the product manual, samples exceeding the quantification range were manually pre-diluted at a dilution factor of 1:10. The Abbott assay also quantifies anti-RBD specific IgG-antibodies (range: 1.0-11,360.0 BAU/mL) and was applied on an Abbott Architect i2000r (Abbott, USA). The assay's threshold for positivity is 7,1 BAU/mL.

Binding reactivities (Roche, Abbott) were compared to a well-described CE-IVD marked surrogate virus neutralization test (GenScript cPass sVNT)^{49–53}. This sVNT quantifies the serum's ability to inhibit spike/ACE-2 interaction; results with an inhibition >30% are considered positive.

The T-cellular activity was estimated in pre- and post-booster whole blood samples using the Quantiferon SARS-CoV-2 assay (Qiagen, Hilden, Germany ^{54–56}). In brief, we quantified the interferon (IFN)γ-release after 21-hour incubation of 1 mL heparinized whole blood portions with two different SARS-CoV-2 antigen mixtures (Ag1, Ag2), and with a negative ("Nil") and a mitogen control, using an ELISA (Qiagen). For each patient and time point, IFNγ-values of the Nil control were subtracted from the SARS-CoV-2 specific antigen mixes results of the samples and presented as Ag1-Nil and Ag2-Nil, respectively.

Statistical analysis

Continuous data are presented as median (interquartile range), and categorical data as counts (percentages). Paired data are compared by Wilcoxon- and Friedman-Tests. Correlations are calculated according to Spearman. Serological assays are compared by Passing-Bablok regressions, which assess differences between two test systems by estimating the slope (systematic proportional differences) and the intercept (systematic constant differences) of a linear regression line. There are no preconditions regarding the distribution of the measured values and the measurement errors to be met. P-values <0.05 were considered statistically significant. All calculations have been performed using MedCalc 19.7

(MedCalc bvba, Ostend, Belgium) and SPSS 26 (IBM, Armonk, USA). Graphs were drawn with Prism 9 (GraphPad, La Jolla, USA).

Results

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Agreement between Roche and Abbott assays depends on the timing of blood collection Blood samples of 50 individuals were collected 3 weeks and 11 weeks after the first dose of AZD1222 (11 weeks = "pre-booster") and 3 weeks after the second dose ("post-booster"). Participant characteristics and binding assay levels at all assessed time points are presented in Tbl. 1 and Fig. 2. In brief, Roche S antibody levels significantly increased from 13.55 BAU/mL (5.21-29.88) at 3 weeks after the first dose to 60.20 (36.38-112.80) directly before the booster (all P<0.0001). 3 weeks after the booster, the median levels were 895.50 (611.80-1681.00). With Abbott, results remained stable between 3 and 11 weeks after the first dose: 42.23 BAU/mL (26.00-78.99) and 32.88 (20.78-53.69), P=0.178, and rose to 171.20 (123.40-278.70) 3 weeks after the booster (P<0.0001). Similar to the Abbott test, the sVNT did not show significant changes between week 3 and 11 after the first dose but significantly increased 3 weeks after the second dose: 47.1 % inhibition (35.5-60.6), 49.0 (35.2-62.4), 95.2 (92.1-97.9), P_{3w post-booster vs. pre-booster or 3w after dose 1}<0.0001. In terms of relative changes in antibody levels for individual participants when comparing 3 and 11 weeks after the first dose versus 3 weeks after the second dose, we observed a 14.2 (8.4-30.8) and 80.8 [27.4-191.0] fold change in titers for Roche, and a 4.9 (3.0-10.1) and 4.5 [2.2-9.9] fold change for Abbott. Thus, the Roche test discriminated increases in antibody levels between weeks 3 and 11 after the first dose: 4.7 (2.2-9.5), whereas Abbott did not: 0.8 (0.5-1.4). 3 weeks after the first dose, results from Roche and Abbott binding assays showed a moderate correlation (ρ=0.755, P<0.0001). Passing-Bablok regression analysis revealed the following equation: Abbott = 7.4 + 2.99*Roche, whereby only the slope of the equation was statistically significant (2.06 – 17); intercept: -4.0 – 13.9). The agreement between both tests improved markedly 11 weeks after the

first dose, with the correlation coefficient rising to ρ =0.902, P<0.0001. Passing-Bablok regression revealed that BAU/mL derived from Abbott were approximately half those measured by Roche: Abbott = 1.1 + 0.50 * Roche (intercept: -2.4 – 5.5, slope: 0.43 – 0.56). 3 weeks after dose 2, the correlation between Roche and Abbott results remained excellent (ρ =0.950, P<0.0001); however, the conversion between the values changed again, with Roche values approximately 5-6 times higher than Abbott results: Abbott = 13.3 + 0.178 * Roche (intercept: -4.5 – 29.5; slope: 0.16 – 0.20). (Figure 3)

Correlation between binding assay and sVNT results

Next, we aimed to determine which of the two binding assays correlated better with neutralizing antibodies, particularly 3 weeks after the first dose, where the agreement between Roche and Abbott results was poorest. Neutralizing antibodies were estimated using the CE-IVD labeled cPass sVNT, with 30% inhibition as the threshold for positivity. 3w after the first dose, 6/50 (12%) participants yielded results below this threshold, with a median inhibition of 47.1 % (35.5-60.6). At week 11, directly before the booster, 4 of them rose above 30% inhibition, but two with initially positive results decreased below the threshold, resulting in a total of 4 individuals (8%) below 30% inhibition. The median neutralizing capacity remained nearly unchanged at an inhibition of 49.0 % (35.2-62.4). 3w after the booster dose, all but one participant presented with at least medium neutralizing capacity (>60%, see Fig. 2). The median increased to 95.2 % inhibition (92.1-97.9) at week 3 post booster; see Tbl. 1 and Fig. 2b.

As shown in Fig. 4, sVNT percent inhibition at 3 weeks after the first dose correlated with the Abbott assay at p=0.887, P<0.0001; in contrast, the correlation with the Roche test was slightly lower at p=0.666 (P<0.0001). At 11 weeks after the first dose, sVNT results correlated very well with both assays (Abbott: p=0.930, Roche: p=0.894, both P<0.0001). Similar results were observed at 3 weeks after the booster (Abbott: p=0.877, Roche: p=0.837, both P<0.0001).

These data suggest that qualitative differences between early and late SARS-CoV-2 antibodies may affect the comparability of serological tests.

Relative changes of T-cellular responses, but not absolute IFNy-levels, correlate with

antibody levels

Finally, we examined the interactions between T-cellular and antibody responses (quantified with the Abbott and the Roche test). For this purpose, we compared the changes between the time before the booster (=11 after the first dose) and the time after the booster (3 weeks after the second dose). IFNy-response to both used antigen mixtures (Ag1 and Ag2) increased after the booster shot: Ag1-Nil 0.10 IU/mL (0.05 – 0.16) to 0.15 IU/mL (0.09 – 0.32), P<0.0001; Ag2-Nil 0.16 IU/mL (0.09 – 0.31) to 0.31 IU/mL (0.16 – 0.98), see Fig. 3 and Tbl. 1. Levels from both antigen mixtures correlated well with each other (pre-booster ρ =0.725, P<0.0001; post-booster ρ =0.775, P<0.0001), see Fig. 5. Moreover, pre-booster levels were in good agreement with post-booster levels (Ag1-Nil ρ =0.786, P<0.0001; Ag2-Nil ρ =0.832, P<0.0001).

Pre-booster interferon γ (IFN γ)-levels only weakly correlated with antibody levels. In fact, most correlations lacked statistical significance, and no relevant correlation was found 3 weeks after the booster. In contrast, the relative changes of cellular and binding assay antibody responses, calculated as 100^* (post-booster – pre-booster)/pre-booster, correlated significantly after incubation with Ag2; however, for Ag1 statistical significance could not be reached (see Tbl. 2). Interestingly, no such correlation was observed for the sVNT.

Discussion

SARS-CoV-2 specific anti-spike protein assays have been and are still widely used for serological studies⁵⁷. In contrast to seroprevalence studies, where discriminating between positive and negative is usually sufficient, quantitative results are needed to adequately describe the response to SARS-CoV-2 vaccines and, ideally, to find a protective correlate^{19,58}. However, there is a major obstacle on the way to such a protection correlate: the need for comparability of quantitative measurement results of different SARS-

CoV-2 antibody tests^{10,11}. In the present work, we compared two commercially available and broadly used CE-IVD marked SARS-CoV-2 antibody assays (Roche and Abbott). Both assays quantitate antibodies directed against the RBD domain of the SARS-CoV-2 spike protein and were referenced against the first WHO standard for SARS-CoV-2 antibodies, thus providing results in BAU/mL. We demonstrated in a previous study after vaccination with BNT162b that despite the standardization of SARS-CoV-2 antibody assays according to the first WHO standard for SARS-CoV-2 antibodies, the numerical values of different test systems are not interchangeable²⁷. In the present work, we show for the first time that the problem of comparability is even more profound because the conversion of results may change dramatically with the time interval from vaccination. Using samples from 50 individuals vaccinated with AZD1222, we could show that both assays detected SARS-CoV-2 specific antibodies in all but two participants 3 weeks after the first dose. Both nonresponders were taking immunosuppressive drugs, which numerous studies have shown can lead to a decreased to absent response to the vaccine⁵⁹⁻⁶¹. However, after the booster dose, the antibody levels markedly increased and reached detectable levels in all participants (Table 1 and Figure 2A). So, in contrast to people with previous COVID^{62–65}, the second dose was required in our SARS-CoV-2 naïve population (negative for anti-nucleocapsid antibodies at all timepoints) to induce high antibody levels. The median relative change of individual antibody levels 3 weeks after the first versus 3 weeks after the second dose was nearly 20-times higher for Roche than for Abbott (80.8 vs. 4.5-fold change); see also Figure 2B. Despite targeting the same antigen (RBD) and converting to the same units (BAU/mL) using the first WHO standard for SARS-CoV-2 antibodies, not even the relative increases in antibody levels turned out to be comparable. The limited comparability of serological assays after vaccination is not specific for the AstraZeneca vaccine, as it was also observed after immunization with Pfizer/BioNTech BNT162b2²⁷.

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Furthermore, when looking at the difference between 3 and 11 weeks after the first vaccination dose, it was found that both the Abbott test and the cPass sVNT did not detect an increase in antibodies (Figure 2). In contrast, antibody levels measured by the Roche test increased >4-fold during this period. This discrepancy could be either explained by the inability of the Abbott and sVNT assays to distinguish such small changes in antibody concentration or the possibility that the Roche assay detects not only quantitative but also qualitative changes of the antibodies formed. Because previous studies failed to demonstrate a continuous increase in antibody levels for AZD1222 later than three weeks after vaccination, the Roche total antibody sandwich assay may also be sensitive to qualitative changes in nascent antibodies, in contrast to the Abbott IgG-specific assay^{16,66}. This hypothesis is also supported by the observation that in direct comparison with the sVNT, the Roche assay underestimated inhibitory capacities at week 3 (Figure 4), which is discussed in detail below. Thus, overall, the assays studied show significant differences in the kinetics of antibody levels, which has been reported previously but was only rarely demonstrated from the same sample with different assays^{28,67}. Although the correlation between Roche and Abbott improved over time, their relationship changed significantly depending on the time of blood sampling (Figure 3). At the first time point, Roche measured three times lower values in BAU/mL than the Abbott assay, 11 weeks after the first dose, Roche measured twice as high as Abbott, and finally, after the booster, Roche was median 5-6 times higher than Abbott. As shown in numerous studies before, detection of SARS-CoV-2 anti-spike binding antibodies correlates well with the presence of functional neutralizing antibodies, so we wanted to examine differences between Roche and Abbott assays in this regard ^{68–73}. The agreement between the results of the binding antibody assays and the neutralization test surrogate was generally good (Figure 4). In particular, at 11 weeks after the first vaccination, the correlation was excellent; after the booster, the correlation was technically limited due to many participants reaching the plateau of the sVNT. However, the worst correlation was found for the first antibody response 3 weeks after the first dose, and here Roche

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

performed significantly worse than Abbott. This finding may be important because the improvement in Roche/sVNT correlation from ρ=0.666 to ρ=0.894 between 3 and 11 weeks after the first dose may indicate reduced sensitivity of the Roche assay for early antibodies. In other words, the discrepancy mentioned above that only Roche showed increasing antibody levels between 3 and 11 weeks after the first dose, while the other two tests showed identical or even slightly decreasing levels (Figure 2), could mean that the Roche test requires more matured antibodies to allow binding. It seems understandable that the binding of antibodies to two antigens, as necessary in the Roche sandwich test, places higher demands on the binding ability of antibodies than is the case in a typical anti-IgG-based detection method. In line with previous studies, the second dose of AZD1222 substantially enhanced the initial antibody response in our cohort ^{31,66,74}. Therefore, we wanted to investigate the relationship between the antibody levels and the cellular responses elicited by the booster. For this purpose, we used a SARS-COV-2 Quantiferon IFN-y release assay similar to those known from tuberculosis diagnostics and compared the pre-booster and post-booster timepoints. As previously shown⁷⁵, the second vaccination dose induced an increase in cellular reactivity (Figure 5). However, we found only weak, mostly statistically non-significant correlations between antibody levels and IFN- γ levels before the booster and no correlation at all after the booster (Table 2). In contrast, the percent cellular response (fold change) to the booster correlated significantly with the percent antibody response (p=0.33 for both binding assays), see Table 2. This finding suggests that the increase of antibodies after a booster shot, which is detected by both binding assays, can be substantiated by an accompanying cellular reaction. In contrast, we found no correlation between the relative changes in cellular and sVNT response, which might be partly explained by the limited measurement range of the sVNT. However, since not all antibodies formed are functionally active neutralizing antibodies (NAbs), even not all of those specifically directed against the RBD domain of the

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

spike protein, the binding antibodies may be superior to the measurement of NAbs here as a correlate for cellular activation.

This study has several strengths and limitations: although 50 participants might be considered a relatively small cohort, we have shown in previous work that this number is sufficient for such comparative approaches and that our data could be replicated in much larger cohorts^{27,76}. One strength of our study is that we followed exact time points for blood sampling in the context of a prospective observational study. Furthermore, our cohort using AZD1222 (inducing significantly lower median antibody levels than, e.g., BNT162b2) has the advantage of a broader distribution of values across the measurable spectrum with a very low proportion of results above 1,000 BAU/mL. As this value represents the upper limit of referencing with the WHO SARS-CoV-2 antibody standard, a linear relationship is no longer guaranteed for values above this, leading to unwanted biases in comparing different antibody tests.

In summary, with the present work, we show for the first time that the comparability of quantitative anti-spike SARS-CoV-2 antibody tests is highly dependent on the timing of blood collection. Therefore, it does not seem feasible to compare different quantitative SARS-COV-2 antibody results without standardization of the time of collection.

Acknowledgments

We thank all sample donors for their valuable contributions. We further thank Martina Trella, Susanne Keim, Borka Radovanovic-Petrova, Monika Martiny, Jadwiga Konarski, Bernhard Haunold, Maedeh Iravany, and Shohreh Lashgari for perfect technical and administrative assistance. The MedUni Wien Biobank is part of the Austrian biobanking consortium BBMRI.at.

- 291 The Department of Laboratory Medicine received compensation for advertisement on scientific
- 292 symposia from Roche and Abbott and holds a grant for evaluating an in vitro diagnostic device from
- 293 Roche.

295

There was no specific funding received for the present work.

References

- 296 1 Cloeckaert Axel, Kuchler Karl. Grand Challenges in Infectious Diseases: Are We Prepared for Worst-Case
- 297 Scenarios? Front Microbiol 2020;11:613383. Doi: 10.3389/fmicb.2020.613383.
- 298 2 Krammer F. SARS-CoV-2 vaccines in development. *Nature* 2020;586(7830):516–27. Doi:
- 299 10.1038/s41586-020-2798-3.
- 300 3 Jackson L. A., Anderson E. J., Rouphael N. G., Roberts P. C., Makhene M., Coler R. N., et al. An mRNA
- 301 Vaccine against SARS-CoV-2 Preliminary Report. New Engl J Med 2020;383(20):1920–31. Doi:
- 302 10.1056/nejmoa2022483.
- 4 Walsh Edward E., Jr. Robert W. Frenck, Falsey Ann R., Kitchin Nicholas, Absalon Judith, Gurtman
- 304 Alejandra, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New Engl J
- 305 *Med* 2020;383(25):2439–50. Doi: 10.1056/nejmoa2027906.
- 5 Stringhini S., Wisniak A., Piumatti G., Azman A. S., Lauer S. A., Baysson H., et al. Seroprevalence of anti-
- 307 SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*
- 308 2020;396(10247):313–9. Doi: 10.1016/s0140-6736(20)31304-0.
- 309 6 Buss L. F., A. Jr. Prete C., Abrahim C. M. M., A. Jr. Mendrone, Salomon T., Almeida-Neto C. de, et al.
- 310 Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic.
- 311 *Science* 2021;371(6526):288–92. Doi: 10.1126/science.abe9728.

- 312 7 Pollan M., Perez-Gomez B., Pastor-Barriuso R., Oteo J., Hernan M. A., Perez-Olmeda M., et al.
- 313 Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological
- 314 study. Lancet 2020;396(10250):535–44. Doi: 10.1016/s0140-6736(20)31483-5.
- 8 Wang H., Ai J., Loeffelholz M. J., Tang Y. W., Zhang W. Meta-analysis of diagnostic performance of
- 316 serology tests for COVID-19: impact of assay design and post-symptom-onset intervals. *Emerg Microbes*
- 317 *Infec* 2020;9(1):2200–11. Doi: 10.1080/22221751.2020.1826362.
- 318 9 Vabret Nicolas, Britton Graham J., Gruber Conor, Hegde Samarth, Kim Joel, Kuksin Maria, et al.
- 319 Immunology of COVID-19: Current State of the Science. *Immunity* 2020;52(6):910–41. Doi:
- 320 10.1016/j.immuni.2020.05.002.
- 321 10 Gundlapalli A. V., Salerno R. M., Brooks J. T., Averhoff F., Petersen L. R., McDonald L. C., et al. SARS-
- 322 CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. Open Forum
- 323 Infect Dis 2021;8(1):ofaa555. Doi: 10.1093/ofid/ofaa555.
- 324 11 Kristiansen Paul A, Page Mark, Bernasconi Valentina, Mattiuzzo Giada, Dull Peter, Makar Karen, et al.
- 325 WHO International Standard for anti-SARS-CoV-2 immunoglobulin. *Lancet* 2021. Doi: 10.1016/s0140-
- 326 6736(21)00527-4.
- 327 12 Collier Ai-ris Y., McMahan Katherine, Yu Jingyou, Tostanoski Lisa H., Aguayo Ricardo, Ansel Jessica, et
- al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. Jama 2021;325(23).
- 329 Doi: 10.1001/jama.2021.7563.
- 13 Collier Dami A., Ferreira Isabella A. T. M., Kotagiri Prasanti, Datir Rawlings, Lim Eleanor, Touizer
- 331 Emma, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature*
- 332 2021:1–9. Doi: 10.1038/s41586-021-03739-1.

333 14 Jeewandara Chandima, Kamaladasa Achala, Pushpakumara Pradeep Darshana, Jayathilaka Deshni, 334 Aberathna Inoka Sepali, Danasekara Danasekara Rallage Saubhagya Rasikangani, et al. Immune 335 responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nat Commun 336 2021;12(1):4617. Doi: 10.1038/s41467-021-24579-7. 337 15 Schmidt Tina, Klemis Verena, Schub David, Mihm Janine, Hielscher Franziska, Marx Stefanie, et al. 338 Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med 339 2021:1-6. Doi: 10.1038/s41591-021-01464-w. 340 16 Wei Jia, Stoesser Nicole, Matthews Philippa C., Ayoubkhani Daniel, Studley Ruth, Bell Iain, et al. 341 Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United 342 Kingdom. *Nat Microbiol* 2021:1–10. Doi: 10.1038/s41564-021-00947-3. 343 17 Pegu Amarendra, O'Connell Sarah, Schmidt Stephen D., O'Dell Sijy, Talana Chloe A., Lai Lilin, et al. 344 Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 345 2021:eabj4176. Doi: 10.1126/science.abj4176. 346 18 Krammer Florian. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med 347 2021;27(7):1147-8. Doi: 10.1038/s41591-021-01432-4. 348 19 Corbett Kizzmekia S., Nason Martha C., Flach Britta, Gagne Matthew, O'Connell Sarah, Johnston 349 Timothy S., et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in 350 nonhuman primates. Science 2021:eabj0299. Doi: 10.1126/science.abj0299. 351 20 Blain Hubert, Tuaillon Edouard, Gamon Lucie, Pisoni Amandine, Miot Stéphanie, Rolland Yves, et al. 352 Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The 353 CONsort-19 study. Allergy 2021. Doi: 10.1111/all.15007.

354 21 Tzarfati Katrin Herzog, Gutwein Odit, Apel Arie, Rahimi-Levene Naomi, Sadovnik Maya, Harel Lotem, 355 et al. BNT162b2 COVID-19 Vaccine is significantly less effective in patients with hematologic 356 malignancies. Am J Hematol 2021. Doi: 10.1002/ajh.26284. 357 22 Prendecki Maria, Clarke Candice, Edwards Helena, McIntyre Stacey, Mortimer Paige, Gleeson Sarah, 358 et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021:annrheumdis-2021-220626. Doi: 10.1136/annrheumdis-2021-220626. 359 360 23 Mrak Daniel, Tobudic Selma, Koblischke Maximilian, Graninger Marianne, Radner Helga, Sieghart 361 Daniela, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune 362 responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 2021:annrheumdis-2021-363 220781. Doi: 10.1136/annrheumdis-2021-220781. 364 24 S Guerrieri, S Lazzarin, C Zanetta, A Nozzolillo, M Filippi, L Moiola. Serological response to SARS-CoV-2 365 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life 366 experience. J Neurol 2021:1-5. Doi: 10.1007/s00415-021-10663-x. 367 25 Lacson Eduardo, Argyropoulos Christos, Manley Harold, Aweh Gideon, Chin Andrew, Salman Loay, et 368 al. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. J Am Soc Nephrol 2021:ASN.2021040432. Doi: 369 10.1681/asn.2021040432. 370 26 Stampfer Samuel D., Goldwater Marissa-Skye, Jew Scott, Bujarski Sean, Regidor Bernard, Daniely 371 David, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. 372 Leukemia 2021:1-8. Doi: 10.1038/s41375-021-01354-7.

27 Perkmann Thomas, Perkmann-Nagele Nicole, Koller Thomas, Mucher Patrick, Radakovics Astrid,

Marculescu Rodrig, et al. Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-

373

- Head Comparison of Five Quantitative Assays. *Microbiol Spectr* 2021;9(1):e00247-21. Doi:
- 376 10.1128/spectrum.00247-21.
- 377 28 Lukaszuk Krzysztof, Kiewisz Jolanta, Rozanska Karolina, Dabrowska Malgorzata, Podolak Amira, Jakiel
- 378 Grzegorz, et al. Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the
- Humoral Response to Vaccination. Nato Adv Sci Inst Se 2021;9(8):840. Doi: 10.3390/vaccines9080840.
- 380 29 Meo Ashley Di, Miller Jessica J, Fabros Ansel, Brinc Davor, Hall Victor, Pinzon Natalia, et al. Evaluation
- 381 of Three anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response. J Appl Laboratory
- 382 *Medicine* 2021:jfab087. Doi: 10.1093/jalm/jfab087.
- 383 30 Eyre David W., Lumley Sheila F., Wei Jia, Cox Stuart, James Tim, Justice Anita, et al. Quantitative SARS-
- 384 CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection
- 385 status. Clin Microbiol Infec 2021. Doi: 10.1016/j.cmi.2021.05.041.
- 386 31 Perkmann Thomas, Perkmann-Nagele Nicole, Mucher Patrick, Radakovics Astrid, Repl Manuela, Koller
- Thomas, et al. Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but
- 388 not for AZD1222. *Int J Infect Dis* 2021. Doi: 10.1016/j.ijid.2021.07.063.
- 389 32 Fraley Elizabeth, LeMaster Cas, Geanes Eric, Banerjee Dithi, Khanal Santosh, Grundberg Elin, et al.
- 390 Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and
- 391 seronegative individuals. *Bmc Med* 2021;19(1):169. Doi: 10.1186/s12916-021-02055-9.
- 33 Buonfrate Dora, Piubelli Chiara, Gobbi Federico, Martini Davide, Bertoli Giulia, Ursini Tamara, et al.
- 393 Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care
- workers, with or without prior SARS-CoV-2 infection: a prospective study. Clin Microbiol Infec 2021. Doi:
- 395 10.1016/j.cmi.2021.07.024.

396 34 Salvagno Gian Luca, Henry Brandon M., Pighi Laura, Nitto Simone De, Gianfilippi Gian Luca, Lippi 397 Giuseppe. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 398 vaccination in healthcare workers. J Infection 2021;83(2):e4-5. Doi: 10.1016/j.jinf.2021.06.024. 399 35 Kaneko Shun, Kurosaki Masayuki, Sugiyama Toru, Takahashi Yuka, Yamaguchi Yoshimi, Nagasawa 400 Masayuki, et al. The dynamics of quantitative SARS-CoV-2 anti-spike IgG response to BNT162b2 401 vaccination. J Med Virol 2021. Doi: 10.1002/jmv.27231. 402 36 Wheeler Sarah E., Shurin Galina V., Yost Mary, Anderson Adam, Pinto Lisa, Wells Alan, et al. 403 Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr 404 2021;9(1):e00341-21. Doi: 10.1128/spectrum.00341-21. 405 37 Tré-Hardy Marie, Cupaiolo Roberto, Wilmet Alain, Beukinga Ingrid, Blairon Laurent. Waning 406 antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing 407 immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers. J Infection 408 2021. Doi: 10.1016/j.jinf.2021.06.017. 409 38 Borobia Alberto M, Carcas Antonio J, Pérez-Olmeda Mayte, Castaño Luis, Bertran María Jesús, García-410 Pérez Javier, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed 411 participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 2021. 412 Doi: 10.1016/s0140-6736(21)01420-3. 413 39 Callegaro Annapaola, Borleri Daniela, Farina Claudio, Napolitano Gavino, Valenti Daniela, Rizzi Marco, 414 et al. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection. J Med Virol 2021. Doi: 10.1002/jmv.26982. 415

40 Michos Athanasios, Tatsi Elizabeth-Barbara, Filippatos Filippos, Dellis Charilaos, Koukou Dimitra,

Efthymiou Vasiliki, et al. Association of total and neutralizing SARS-CoV-2 spike -Receptor Binding

416

- 418 Domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and
- 419 2nd doses of the BNT162b2 vaccine. *Vaccine* 2021. Doi: 10.1016/j.vaccine.2021.07.067.
- 420 41 Douxfils Jonathan, Gillot Constant, Mullier François, Favresse Julien. Post-SARS-CoV-2 vaccination
- 421 specific antibody decrease Thresholds for determining seroprevalence and seroneutralization differ. J
- 422 *Infection* 2021. Doi: 10.1016/j.jinf.2021.08.023.
- 423 42 Ebinger Joseph E., Fert-Bober Justyna, Printsev Ignat, Wu Min, Sun Nancy, Prostko John C., et al.
- 424 Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
- 425 Nat Med 2021:1–4. Doi: 10.1038/s41591-021-01325-6.
- 426 43 Konstantinidis Theocharis G, Zisaki Stavroula, Mitroulis Ioannis, Konstantinidou Eleni, Kontekaki
- 427 Eftychia G, Romanidou Gioulia, et al. Levels of Produced Antibodies after Vaccination with mRNA
- 428 Vaccine; Effect of Previous Infection with SARS-CoV-2. *J Clin Medicine* 2021;10(13):2842. Doi:
- 429 10.3390/jcm10132842.
- 430 44 Haslacher H., Gerner M., Hofer P., Jurkowitsch A., Hainfellner J., Kain R., et al. Usage Data and
- 431 Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien
- 432 Biobank. *Biopreserv Biobank* 2018;16(6):477–82. Doi: 10.1089/bio.2018.0032.
- 433 45 Perkmann Thomas, Perkmann-Nagele Nicole, Breyer Marie-Kathrin, Breyer-Kohansal Robab,
- 434 Burghuber Otto C, Hartl Sylvia, et al. Side by side comparison of three fully automated SARS-CoV-2
- antibody assays with a focus on specificity. Clin Chem 2020;66(11):hvaa198-. Doi:
- 436 10.1093/clinchem/hvaa198.
- 437 46 Higgins V., Fabros A., Kulasingam V. Quantitative measurement of anti-SARS-CoV-2 antibodies:
- 438 Analytical and clinical evaluation. *J Clin Microbiol* 2021;59(4). Doi: 10.1128/jcm.03149-20.

439 47 Narasimhan Madhusudhanan, Mahimainathan Lenin, Araj Ellen, Clark Andrew E, Markantonis John, 440 Green Allen, et al. Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and 441 IgM assays among infected, recovered, and vaccinated groups. J Clin Microbiol 2021. Doi: 442 10.1128/jcm.00388-21. 443 48 English Emma, Cook Laura E, Piec Isabelle, Dervisevic Samir, Fraser William D, John W Garry. 444 Performance of the Abbott SARS-CoV-2 IgG II Quantitative antibody assay including the new Variants of 445 Concern (VOC 202012/V1 (UK) and VOC 202012/V2 (South Africa)): And first steps towards global 446 harmonization of COVID-19 antibody methods. J Clin Microbiol 2021:JCM0028821. Doi: 447 10.1128/jcm.00288-21. 448 49 Nandakumar Vijayalakshmi, Profaizer Tracie, Lozier Bucky K, Elgort Marc G, Larragoite Erin T, Williams 449 Elizabeth S C P, et al. Evaluation of a Surrogate ELISA- Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation with IgG 450 451 Commercial Serology Assays. Arch Pathol Lab Med 2021. Doi: 10.5858/arpa.2021-0213-sa. 452 50 Papenburg Jesse, Cheng Matthew P, Corsini Rachel, Caya Chelsea, Mendoza Emelissa, Manguiat 453 Kathy, et al. Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe 454 Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay. Open Forum Infect Dis 2021. Doi: 10.1093/ofid/ofab220. 455 456 51 Murray Matthew J, McIntosh Megan, Atkinson Claire, Mahungu Tabitha, Wright Edward, Chatterton 457 Wendy, et al. Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies

using a pseudotyped virus assay. J Infection 2021. Doi: 10.1016/j.jinf.2021.03.010.

459 52 Taylor Sean C, Hurst Beth, Charlton Carmen L, Bailey Ashley, Kanji Jamil N, McCarthy Mary K, et al. A 460 New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing 461 Antibody Response Detection. J Clin Microbiol 2021;59(4). Doi: 10.1128/jcm.02438-20. 462 53 Tan Chee Wah, Chia Wan Ni, Qin Xijian, Liu Pei, Chen Mark I.-C., Tiu Charles, et al. A SARS-CoV-2 463 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein 464 interaction. Nat Biotechnol 2020;38(9):1073–8. Doi: 10.1038/s41587-020-0631-z. 465 54 Schramm René, Costard-Jäckle Angelika, Rivinius Rasmus, Fischer Bastian, Müller Benjamin, Boeken 466 Udo, et al. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 467 in cardiothoracic transplant recipients. Clin Res Cardiol 2021:1–8. Doi: 10.1007/s00392-021-01880-5. 468 55 Re Daniel, Seitz-Polski Barbara, Carles Michel, Brglez Vesna, Graça Daisy, Benzaken Sylvia, et al. 469 Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid 470 malignancies. Medrxiv 2021:2021.07.18.21260669. Doi: 10.1101/2021.07.18.21260669. 471 56 Jaganathan Soumya, Stieber Francis, Rao Sonia N, Nikolayevskyy Vladyslav, Manissero Davide, Allen 472 Nadia, et al. Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total 473 Test in Recently Vaccinated Individuals 2021. Doi: 10.21203/rs.3.rs-623620/v1. 474 57 Arora R. K., Joseph A., Wyk J. Van, Rocco S., Atmaja A., May E., et al. SeroTracker: a global SARS-CoV-2 475 seroprevalence dashboard. Lancet Infect Dis 2021;21(4):e75-6. Doi: 10.1016/s1473-3099(20)30631-9. 476 58 Bergwerk Moriah, Gonen Tal, Lustig Yaniv, Amit Sharon, Lipsitch Marc, Cohen Carmit, et al. Covid-19 477 Breakthrough Infections in Vaccinated Health Care Workers. New Engl J Med 2021. Doi:

478

10.1056/nejmoa2109072.

- 479 59 Benotmane Ilies, Gautier Gabriela, Perrin Peggy, Olagne Jérôme, Cognard Noëlle, Fafi-Kremer Samira,
- 480 et al. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant
- 481 Recipients With Minimal Serologic Response to 2 Doses. *Jama* 2021;326(11). Doi:
- 482 10.1001/jama.2021.12339.
- 483 60 Louapre Céline, Ibrahim Michella, Maillart Elisabeth, Abdi Basma, Papeix Caroline, Stankoff Bruno, et
- 484 al. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple
- sclerosis or neuromyelitis optica spectrum disorders. J Neurology Neurosurg Psychiatry 2021:jnnp-2021-
- 486 326904. Doi: 10.1136/jnnp-2021-326904.
- 487 61 Boekel Laura, Steenhuis Maurice, Hooijberg Femke, Besten Yaëlle R, Kempen Zoé L E van, Kummer
- 488 Laura Y, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases
- in the Netherlands: a substudy of data from two prospective cohort studies. *Lancet Rheumatology* 2021.
- 490 Doi: 10.1016/s2665-9913(21)00222-8.
- 491 62 Perkmann Thomas, Perkmann-Nagele Nicole, Koller Thomas, Mucher Patrick, Radakovics Astrid, Wolzt
- 492 Michael, et al. Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection. Eur J Clin
- 493 *Invest* 2021. Doi: 10.1111/eci.13632.
- 494 63 Prendecki Maria, Clarke Candice, Brown Jonathan, Cox Alison, Gleeson Sarah, Guckian Mary, et al.
- 495 Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2
- 496 vaccine. *Lancet* 2021;397(10280):1178—1181. Doi: 10.1016/s0140-6736(21)00502-x.
- 497 64 Krammer Florian, Srivastava Komal, Alshammary Hala, Amoako Angela A., Awawda Mahmoud H.,
- 498 Beach Katherine F., et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2
- 499 mRNA Vaccine. New Engl J Med 2021. Doi: 10.1056/nejmc2101667.

500 65 Bradley Todd, Grundberg Elin, Selvarangan Rangaraj, LeMaster Cas, Fraley Elizabeth, Banerjee Dithi, 501 et al. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. New Engl J Med 2021. Doi: 502 10.1056/nejmc2102051. 503 66 Barrett Jordan R., Belij-Rammerstorfer Sandra, Dold Christina, Ewer Katie J., Folegatti Pedro M., 504 Gilbride Ciaran, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose 505 induces multifunctional antibody responses. Nat Med 2021;27(2):279-88. Doi: 10.1038/s41591-020-506 01179-4. 507 67 Danese Elisa, Montagnana Martina, Salvagno Gian Luca, Gelati Matteo, Peserico Denise, Pighi Laura, 508 et al. Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA. J Med Biochem 2021. Doi: 10.5937/jomb0-31475. 509 510 68 Irsara Christian, Egger Alexander E, Prokop Wolfgang, Nairz Manfred, Loacker Lorin, Sahanic Sabina, et 511 al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved 512 sensitivity and a good correlation with virus neutralization titers. Clin Chem Laboratory Medicine Cclm 513 2021;0(0):000010151520210214. Doi: 10.1515/cclm-2021-0214. 514 69 Boonyaratanakornkit J., Morishima C., Selke S., Zamora D., McGuffin S., Shapiro A. E., et al. Clinical, 515 laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 516 convalescent plasma donor candidates. J Clin Invest 2021;131(3). Doi: 10.1172/jci144930. 517 70 Muecksch F., Wise H., Batchelor B., Squires M., Semple E., Richardson C., et al. Longitudinal 518 Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.

J Infect Dis 2021;223(3):389–98. Doi: 10.1093/infdis/jiaa659.

- 71 Luchsinger Larry L, Ransegnola Brett P, Jin Daniel K, Muecksch Frauke, Weisblum Yiska, Bao Weili, et
 al. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered
 COVID-19 Patients. *J Clin Microbiol* 2020;58(12). Doi: 10.1128/jcm.02005-20.
 72 Seow J., Graham C., Merrick B., Acors S., Pickering S., Steel K. J. A., et al. Longitudinal observation and
- decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* 2020;5(12):1598–607. Doi: 10.1038/s41564-020-00813-8.
- 73 Szabó Zsófia, Szabó Tamás, Bodó Kornélia, Kemenesi Gábor, Földes Fanni, Kristóf Katalin, et al.
 Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in

COVID-19 recovered plasma donors. Pract Laboratory Medicine 2021;25:e00222. Doi:

10.1016/j.plabm.2021.e00222.

528

529

534

535

536

- 74 Barros-Martins Joana, Hammerschmidt Swantje I., Cossmann Anne, Odak Ivan, Stankov Metodi V.,
 Ramos Gema Morillas, et al. Immune responses against SARS-CoV-2 variants after heterologous and
 homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat Med* 2021:1–5. Doi: 10.1038/s41591-02101449-9.
 - 75 Ramasamy Maheshi N, Minassian Angela M, Ewer Katie J, Flaxman Amy L, Folegatti Pedro M, Owens Daniel R, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* 2021;396(10267):1979–93. Doi: 10.1016/s0140-6736(20)32466-1.
- 76 Jabal K. Abu, Ben-Amram H., Beiruti K., Batheesh Y., Sussan C., Zarka S., et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.
- 541 Eurosurveillance 2021;26(6):2100096. Doi: 10.2807/1560-7917.es.2021.26.6.2100096.

Legends to Figures and Tables

542

543 Fig. 1: Study flow chart. Anti-Spike(S)-antibody (Ab) assays: Roche S, Abbott S. Infection with SARS-CoV-2 544 was ruled out by detection of antibodies against the SARS-CoV-2 nucleocapsid (N) using the Roche N 545 ECLIA. W... weeks; sVNT... surrogate virus neutralization test. 546 Fig. 2: A Antibody levels (Roche, Abbott) and percent inhibition in a surrogate virus neutralization test 547 (sVNT) 3w (weeks) after the first dose of AZD1222, pre-booster (11w after the first dose), and 3w post-548 booster. Dotted Lines indicate the test systems' thresholds for positivity (Roche: 0.8 BAU/mL, Abbott 7.1 549 BAU/mL, sVNT 30%) and, in the case of Roche, the upper level of quantification (2,500 BAU/mL). Green lines represent the group median. ****... P<0.0001 in Wilcoxon tests. B Longitudinal changes of individual 550 551 Roche, Abbott, and cPass surrogate virus neutralization test (sVNT) results: 3w (3 weeks) after the first 552 dose, before the booster dose, and 3w after the booster dose. According to the manufacturers, Roche 553 results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results ≥149,1 BAU/mL 554 correspond to a neutralization titer of at least 1:80; 30% inhibition is considered the sVNTs threshold for 555 positivity. Results are, according to the manufacturer, categorized into low (30-60%), medium (60-90%), 556 and high (>90%) neutralizing capacity (all levels indicated by dotted lines). 557 Fig. 3: A Passing-Bablok regression for Roche and Abbott results; readings were converted to BAU/mL. 558 The dotted lines are the 95% confidence intervals (CI) for the regression lines. The dashed lines represent 559 lines of equality. **B** Linear regression (±95% CI) of logarithmic results from Roche and Abbott. 560 3w... 3 weeks; BAU/mL... binding antibody units per milliliter 561 Fig. 4: Linear regression lines (±95% confidence intervals) for c-pass surrogate virus neutralization test 562 (sVNT) results and logarithmic binding assay results (top panel: Abbott, bottom panel: Roche). The dotted 563 vertical line represents the sVNT's threshold for positivity (30% inhibition). According to the 564 manufacturers, Roche results ≥15 BAU/mL correlate with a positive neutralization test, Abbott results

565	≥149,1 BAU/mL correspond to a neutralization titer of at least 1:80 as indicated by horizontal dotted
566	lines. 3w 3 weeks; BAU/mL binding antibody units per milliliter
567	Fig. 5: A Logarithmic IFNy levels after stimulation of 1mL heparinized whole blood with Quantiferon
568	SARS-CoV-2 antigen mixture 1 (Ag1), antigen mixture 2 (Ag2), Nil (negative control) and mitogen control,
569	as well as Nil-corrected levels (Ag1-Nil, Ag2-Nil). Green lines indicate medians. B Pairwise comparisons of
570	Ag1-Nil and Ag2-Nil in response to the booster shot. **** <0.0001. Green lines indicate medians. \boldsymbol{c} Linear
571	regression curves (±95% confidence intervals) of Ag1-Nil and Ag2-Nil before and after the booster shot.
572	3w 3 weeks
573	Tbl. 1: Participant characteristics and surrogates of humoral (Roche, Abbott, sVNT) and cellular (IFNy)
574	immunity. P-values were derived from Friedman-tests.
575	3w 3 weeks; BAU/mL binding antibody units per milliliter; immunosuppr immunosuppressive; sVNT
575 576	$3w\ 3$ weeks; BAU/mL binding antibody units per milliliter; immunosuppr immunosuppressive; sVNT surrogate virus neutralization test; IFN γ interferon γ
576	surrogate virus neutralization test; IFNγ interferon γ
576 577	surrogate virus neutralization test; IFN γ interferon γ Tbl. 2: Correlation Table. Spearman's ρ of rank correlations between Nil-corrected interferon γ (IFN γ)-

	Median (interquartile range) or counts (%)			
Female sex	43 (86%)			
Age [years]	35.5 (29-49)			
Immunosuppr. drugs	2 (4%)			
	3w post dose 1	pre-booster	3w post-booster	P-value
Roche [BAU/mL]	13.6 (5.2-29.9)	60.2 (36.4-112.8)	895.5 (611.8-1681.0)	<0.0001
Abbott [BAU/mL]	42.2 (26.0-79.0)	32.9 (20.8-53.7)	171.2 (123.4-278.7)	<0.0001
sVNT [% inhibition]	47.1 (35.5-60.6)	49.0 (35.3-62.4)	95.2 (92.1-97.9)	<0.0001
IFNγ Ag1-Nil [IU/mL]		0.10 (0.05-0.16)	0.15 (0.09-0.32)	<0.0001
IFNγ Ag2-Nil [IU/mL]		0.16 (0.09-0.31)	0.31 (0.16-0.98)	<0.0001

Tbl. 1: Participant characteristics and surrogates of humoral (Roche, Abbott, sVNT) and cellular (IFNy) immunity. P-values were derived from Friedman-tests.

3w... 3 weeks; BAU/mL... binding antibody units per milliliter; immunosuppr... immunosuppressive; sVNT... surrogate virus neutralization test; IFNy... interferon y

Pre-booster	Abbott	Roche	sVNT
Pre-booster	ADDOLL	Roche	SVIVI
Ag1-Nil	0.236 (P=0.100)	0.258 (P=0.071)	0.217 (P=0.130)
Ag2-Nil	0.287 (P=0.044)	0.243 (P=0.089)	0.252 (P=0.077)
Post-booster	Abbott	Roche	sVNT
Ag1-Nil	0.037 (P=0.796)	0.101 (P=0.485)	-0.001 (P=0.995)
Ag2-Nil	0.067 (P=0.642)	0.095 (P=0.510)	0.024 (P=0.868)
% response	Abbott	Roche	sVNT
Ag1-Nil	0.251 (P=0.082)	0.247 (P=0.087)	0.196 (P=0.178)
Ag2-Nil	0.333 (P=0.018)	0.325 (P=0.021)	0.164 (P=0.255)

Tbl. 2: Correlation table. Spearman's ρ of rank correlations between Nil-corrected interferon γ (IFN γ)-levels after incubation with Quantiferon SARS-CoV-2 antigen mixtures 1 (Ag1-Nil) or 2 (Ag2-Nil) and antibody levels. sVNT... surrogate virus neutralization test. % response... 100*(post-booster – pre-booster)/pre-booster









